CA Patent

CA2102591C — Hypoglycemic agent

Assigned to Tanabe Pharma Corp · Expires 2000-12-26 · 25y expired

What this patent protects

The present invention is directed to a hypoglycemic agent which comprises as an active ingredient a dihydrochalcone derivative of the formula [I]: (see formula I) wherein Ar is an aryl group, R1 is hydrogen atom or an acyl group, R2 is hydrogen atom, an acyl group or .alpha.-D-…

USPTO Abstract

The present invention is directed to a hypoglycemic agent which comprises as an active ingredient a dihydrochalcone derivative of the formula [I]: (see formula I) wherein Ar is an aryl group, R1 is hydrogen atom or an acyl group, R2 is hydrogen atom, an acyl group or .alpha.-D-glucopyranosyl group, or R1 and R2 may combine together to form a substituted methylene group, R3 and R4 are each hydrogen atom or an acyl group, and a group of the formula: OR5 is a protected or unprotected hydroxy group or a lower alkoxy group, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2102591C
Jurisdiction
CA
Classification
—
Expires
2000-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.